Alivus Life Sciences Signs Shareholders' Agreement with IQGEN-X Pharma
Alivus Life Sciences Ltd has executed a Shareholders' Agreement (SHA) with IQGEN-X Pharma Private Limited and its Continuing Existing Shareholders (CES). The SHA formalizes the mutual understanding regarding inter se rights and obligations stemming from their shareholding. Alivus Life Sciences is in the process of acquiring a 76% stake in IQGEN-X Pharma. Key terms include Alivus's option to buy the remaining 24% stake after five years at a pre-agreed benchmark price. The agreement also outlines board composition with 2 directors from Alivus and 1 from CES, and restricts share transfers. The company states there is no impact on its management or control, and no related party transactions are involved.
Key Highlights
- Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma.
- Shareholders' Agreement executed to define rights and obligations.
- Alivus has an option to acquire remaining 24% stake in 5 years.
- Board composition to be 2 directors from Alivus, 1 from CES.
- No impact on management or control of Alivus Life Sciences.
Price Impact
More from ALIVUS